Skinfold thickness (ST) was measured in 43 children with various forms of growth hormone (GH) deficiency during the first year of GH therapy. The average (and SEM) initial ST, expressed as standard deviation score (SDS) was 1.17 (0.25) for subscapular, 0.63 (0.18) for triceps, and 0.40 (0.21) for bi
Insulin secretion in growth hormone-deficient children and the effect of the sulfonylurea drug glibenclamide on linear growth
β Scribed by E. Heinze; W. Beischer; W. M. Teller
- Publisher
- Springer
- Year
- 1978
- Tongue
- English
- Weight
- 424 KB
- Volume
- 128
- Category
- Article
- ISSN
- 0340-6997
No coin nor oath required. For personal study only.
β¦ Synopsis
The effect of glucose on insulin release and the influence of glibenclamide on linear growth were determined in five growth hormone (STH) deficient children who were treated with human growth hormone. It was found that the administration of 5 I.U. of human growth hormone twice a week improved the defective insulin secretion while prolongation of the week improved the defective insulin secretion while prolongation of the interval between growth hormone injections to 7 days had no effect on beta-cell function. The addition of treatment with 5 mg/day glibenclamide to the regular human growth hormone injections resulted in an increased growth rate in four children while one patient developed hypoglycemic symptoms. The results show that STH-deficient children may benefit from combined treatment with human growth hormone plus glibenclamide.
π SIMILAR VOLUMES
The effect of repeated electroconvulsive shocks (ECS) on growth hormone (GH) secretion was studied in rats. Male Sprague-Dawley animals were given one ECS daily for 10 days under halothane anaesthesia. Control animals were anaesthetised only. GH secretion was studied 24 h after the last ECS or sham
## Abstract ## Objective To determine the effects of chronic deficiency of growth hormone (GH) and insulinβlike growth factor 1 (IGFβ1) on osteoarthritis (OA) severity. ## Methods Thirtyβfive rats were divided into 4 treatment groups at 4 weeks of age: 1 control group (normal GH/IGFβ1 levels [he